Kiniksa Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2016
Revenue	270.26	220.18	38.54	0	0	Upgrade
Revenue Growth (YoY)	22.74%	471.24%	-	-	-	Upgrade
Cost of Revenue	33.41	22.9	9.1	0	0	Upgrade
Gross Profit	236.85	197.29	29.44	0	0	Upgrade
Selling, General & Admin	129.43	97.95	85.95	45.32	34.96	Upgrade
Research & Development	76.1	65.49	99.3	112.04	135	Upgrade
Other Operating Expenses	56.52	24.07	0.84	0	0	Upgrade
Operating Expenses	262.05	187.51	186.08	157.36	169.96	Upgrade
Operating Income	-25.2	9.77	-156.64	-157.36	-169.96	Upgrade
Other Expense / Income	-8.54	-1.25	-0.1	-1.13	-6.05	Upgrade
Pretax Income	-16.65	11.03	-156.54	-156.23	-163.91	Upgrade
Income Tax	-30.74	-172.34	1.39	5.15	-2.05	Upgrade
Net Income	14.08	183.36	-157.92	-161.38	-161.87	Upgrade
Net Income Growth	-92.32%	-	-	-	-	Upgrade
Shares Outstanding (Basic)	70	69	69	62	54	Upgrade
Shares Outstanding (Diluted)	72	70	69	62	54	Upgrade
Shares Change	2.13%	2.69%	10.89%	14.42%	82.92%	Upgrade
EPS (Basic)	0.20	2.64	-2.30	-2.61	-2.99	Upgrade
EPS (Diluted)	0.20	2.60	-2.30	-2.61	-2.99	Upgrade
EPS Growth	-92.31%	-	-	-	-	Upgrade
Free Cash Flow	13.17	5.79	-126.71	-136.82	-161.57	Upgrade
Free Cash Flow Per Share	0.19	0.08	-1.85	-2.21	-2.99	Upgrade
Gross Margin	87.64%	89.60%	76.39%	-	-	Upgrade
Operating Margin	-9.32%	4.44%	-406.38%	-	-	Upgrade
Profit Margin	5.21%	83.28%	-409.72%	-	-	Upgrade
Free Cash Flow Margin	4.87%	2.63%	-328.75%	-	-	Upgrade
Effective Tax Rate	-	-1563.01%	-	-	-	Upgrade
EBITDA	-11.26	16.47	-151.55	-152.42	-160.64	Upgrade
EBITDA Margin	-4.17%	7.48%	-393.19%	-	-	Upgrade
Depreciation & Amortization	5.4	5.44	4.99	3.81	3.28	Upgrade
EBIT	-16.65	11.03	-156.54	-156.23	-163.91	Upgrade
EBIT Margin	-6.16%	5.01%	-406.13%	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).